NCT05267886RecruitingPhase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 346 (estimated)
- First submitted
- 3 Feb 2022
- Start date
- 5 Mar 2022
- Primary completion date
- Dec 2026
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- NCT number
- NCT05267886
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 346
- From 5 Mar 2022 to the primary completion date, Dec 2026
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients presenting with an out-of-hospital cardiac arrest (OHCA)
Other
- Unwilling or unable to obtain informed consent by the participant or substitute decision maker
- Patients who are currently pregnant or breast-feeding
- Administration of milrinone or dobutamine in the 24 hours preceding anticipated randomization
- Severe obstructive valvular lesions, including aortic stenosis and/or mitral stenosis
- Dynamic left ventricular outflow tract obstruction
Who the study is looking for
- Adult patients ≥ 18 years of age admitted to an intensive care unit
- SCAI class C or D cardiogenic shock
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hamilton Health Sciences Coordinator of this site? Confirm its status | Hamilton | Canada | Recruiting |
| University of Ottawa Heart Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Recruiting |
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.